Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Immuron ( (IMRN) ) has provided an announcement.
On November 7, 2025, Immuron Limited announced the application for quotation of 8,495,080 ordinary fully paid securities on the Australian Securities Exchange. These securities were issued as part of a previously announced transaction and purchased by US investors through the US At-The-Market facility. This move is expected to enhance the company’s capital structure and potentially strengthen its market position by increasing its financial flexibility.
The most recent analyst rating on (IMRN) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.
Spark’s Take on IMRN Stock
According to Spark, TipRanks’ AI Analyst, IMRN is a Underperform.
Immuron’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. The technical analysis indicates a bearish trend, with the stock being oversold. Valuation metrics further highlight the company’s financial struggles, with a negative P/E ratio. The lack of earnings call data and corporate events means these components do not influence the score.
To see Spark’s full report on IMRN stock, click here.
More about Immuron
Immuron Limited is a biopharmaceutical company based in Australia, focusing on the development and commercialization of oral immunotherapeutic products for the treatment of gut-mediated diseases. The company operates primarily in the pharmaceutical industry, targeting markets that require innovative treatments for gastrointestinal disorders.
Average Trading Volume: 167,716
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.83M
See more data about IMRN stock on TipRanks’ Stock Analysis page.